Milestone Pharmaceuticals (Canada) a development-stage pharmaceutical company focused on small molecules for atrial arrhythmias and angina, closed a $13M Series B financing. Participants include Pappas Ventures, GO Capital, Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation.

The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science professionals on-line and in-print. Contact arubenstein@rnaventures.com for details.